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Human immunodeficiency virus (HIV) and hepatitis 
B virus (HBV) infections are endemic in sub-Saharan 
Africa,[1] and transmitted via similar routes.[2,3] Both 
infections are of high public health importance. 
Infection with HBV is not always considered in the 
management of HIV infection,[4] although co-infection has been 
associated with increased turnover rate of HIV RNA-increased liver 
morbidity, and complicated HIV pathology.[5-7] On the other hand, 
the use of highly active antiretroviral therapy (HAART) with a 
lamivudine component is used for HIV treatment in South Africa, 
and would be expected to be associated with the development of 
HBV drug-resistant strains, since lamivudine is the sole active drug 
(monotherapy) against HBV.
Several studies have reported the prevalence of HIV/HBV 
co-infection in South Africa. For example, Boyles and Cohen[8] in 
a hospital setting reported a prevalence of 7.1% in Eastern Cape 
Province. They reported male gender and alanine aminotransferase 
as important predictors of HBV infection in HIV-infected patients. 
Hoffmann and colleagues reported a prevalence of 20% among 
male mine workers in several regions of South Africa.[9] In Gauteng 
Province, exposure to HBV, considering HBsAg and anti-HBc, 
of 39% was documented in HIV-positive women.[10] An earlier 
prospective study in Johannesburg showed a 6% infection rate of 
HIV/HBV co-infection.[11]
The prevalence of HIV in Limpopo Province is estimated to be 
17.5%. On the other hand, data are scarce for the prevalence of HBV 
in the general population, and more so in HIV-infected patients. 
Since patients with HIV/HBV co-infection are at higher risk for early 
decompensation of liver disease, liver cirrhosis and hepatocellular 
carcinoma, updating data on the prevalence of HIV/HBV co-infection 
is important to better understand the burden of co-infection relevant 
for patient management, particularly in regions where little data 
exist. The present study was carried out to establish the level of 
HBV exposure in HIV patients, assess the prevalence of HIV/HBV 
co-infection, evaluate the level of HIV patients protected against HBV, 
and assess the response of HBV to the first-line HAART regimen in 
HIV-infected patients in north-eastern South Africa.
Materials and methods
Ethical considerations
Ethical clearance was obtained from the University of Venda’s Health, 
Safety and Research Ethics Committee to use archived confirmed 
HIV-positive samples from the specimen bank in the Department of 
Microbiology, University of Venda. The samples had been stored at 
-80⁰C for less than 2 years.
Study population and sample collection
Initial blood samples were collected in 2008 from antiretroviral-
naïve and -experienced patients (n=380) in Bela Bela (Waterberg 
district), Mankweng (Capricorn district), Musina and Madimbo 
(Vhembe district) in the Limpopo Province of South Africa. 
A subset of 105 patients of the 380 who presented samples 
were drug-experienced. Samples from this group were collected 
for evaluation before treatment initiation and subsequently at 
3-month intervals for 1 year. All the 380 samples were used to 
determine the degree of exposure to HBV; the prevalence of 
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Objective. Hepatitis B virus (HBV) and HIV are endemic infections in many African countries. The objectives of this study were to 
determine the levels of exposure to, and protection from, HBV, as well as the prevalence of HIV/HBV co-infection and the response of HBV 
to highly active anti-retroviral therapy (HAART) in a cross-section of HIV-infected patients in north-eastern South Africa.
Study design. This was a laboratory-based, unmatched study. Three hundred and eighty patients were screened by ELISA for HBsAg, 
anti-HBc and anti-HBs. Samples non-reactive for HBsAg but reactive for anti-HBc were examined for occult HBV infection. Response to 
HAART was assessed by measuring HBV viral loads, seroconversion from HBeAg to anti-HBe, and levels of aminotransferase.
Results. Of the study population of 380, 60% (95% CI 54.8 - 64.9) were exposed to HBV based on HBsAg, anti-HBs or anti-HBc; 20% 
(95% CI 16.1 - 24.4) had active HBV infection, based on HBsAg serology, and 30% (95% CI 25.2 - 35.2) were protected, based on anti-HBs 
levels ≥10 IU/l. Of 181 HBsAg-negative individuals, 61 had HBV occult infection (33.7%, 95% CI 26.9 - 41.1). The differences in prevalence 
were not statistically significant when gender, marital status and CD4+ cell counts were considered. Of 21 patients analysed, 80% showed 
adequate response to the first-line HAART regimen (stavudine/lamivudine/efavirenz or nevirapine) after 12 months of use.
Conclusion. The study confirms the higher level (60%) of exposure to HBV in HIV patients in Limpopo Province, as well as the high 
(20%) prevalence of HBsAg positivity and occult hepatitis B (33.7%). However, further studies are warranted to corroborate the benefit of 
lamivudine-containing HAART regimens, as HIV/HBV co-infected patients have a higher liver-related mortality if hepatitis B is not treated.
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HIV/HBV co-infection; occult HBV infection; and the level of 
protection against HBV. The full group comprised 104 males and 
276 females, aged between 19 and 65 years old, with varying CD4 
counts and stages of HIV disease. The only exclusion criterion was 
inadequate specimen volume for the anticipated assays. The subset 
of samples (n=105) determined to be HIV/HBV co-infected, and 
under D4T/3TC/EFV treatment, were followed as a cohort for a 
year in assessing the efficacy of HIV treatment regimen on HBV 
infection.
Determination of the level of exposure and prevalence of 
HBV in HIV patients
A total of 380 plasma specimens were screened and confirmed 
for HBsAg (a marker for active HBV infection) using the Murex 
HBsAg Version 3 and Murex HBsAg Confirmatory Version 3 
ELISA protocols, respectively (Abbott-Murex, USA) according to the 
manufacturer’s instructions. Exposure to HBV was determined by 
screening for the presence of at least one of the serological markers 
HBsAg, anti-HBc or anti-HBs by means of ELISA.
Determination of occult HBV infections in HIV-infected 
patients
The determination of occult HBV infection was carried out by 
screening HBsAg-negative plasma samples (n=304) for anti-HBc 
using Murex anti-HBc ELISA (Abbott-Murex, USA) according to 
the manufacturer’s instructions. This was followed by amplification 
of HBV core gene using an in-house nested polymerase chain 
reaction (PCR) protocol as previously described.[12] The nested 
PCR amplification product was verified for expected fragment 
size by a 1% ethidium bromide-stained agarose gel electrophoresis 
at a constant voltage of 100 V for 40 minutes, and viewed by UV 
transillumination.
Determination of the level of protection against HBV in 
HIV patients
Protection against HBV was done by the detection and quantification 
of anti-HBs. Screening was performed on 343 HIV-positive plasma 
samples of sufficient volume using Murex anti-HBs ELISA (Abbott-
Murex, USA), according to the manufacturer’s instructions. Samples 
with antibodies ≥10 mIU/ml were considered positive and protective 
against HBV, while samples <10 mIU/ml were considered non-
protective.
Determination of the efficacy of HAART on HBV 
infection in HIV/HBV co-infected patients
This objective was to assess 3 parameters of clinical responses to 
therapy: serological, viral and biochemical responses. Each clinical 
parameter was assessed independently and their results compared for 
consistency of patients’ response to antiretroviral drugs at one year of 
therapy. The same samples were subjected to viral and biochemical 
responses, but biochemical response had some new inclusions for 
the non-consistent samples (reasons for the independent assessment 
of each parameter). Measurements for viral loads and serological 
responses were done before the initiation of therapy and at 44 weeks, 
while biochemical response was assessed before therapy and at 12 and 
24 weeks respectively. Twenty-one HIV/HBV co-infected patients 
who had been on a 4DT/3TC//EFV treatment regimen were used for 
this assessment.
Quantification of viral DNA (viral response)
Quantification of HBV viral load was done using the Cobas Taqman 
48 analyzer (Roche) following DNA extraction using the Cobas 
Taqman Pure Viral Nucleic Acid (Roche) before treatment and at 44 
weeks of treatment.
Serological and biochemical responses
The Elecsys automated platform (Roche) was used to screen for 
HBeAg and anti-HBe before the onset of treatment and at 44 
weeks after the initiation of treatment to evaluate seroconversion 
from HBeAg to anti-HBe. Biochemical response to therapy 
was determined by comparing aminotransferase levels in 
plasma samples before treatment and at 24 weeks into therapy. 
Aminotransferase values were obtained from available HIV 
treatment evaluation data from the patients. A response was 
characterised by a return of abnormally high aminotransferase to 
the normal range (3 - 35 IU/l).
Results
Level of exposure, and prevalence of HBV infection
The level of exposure to HBV (presence of any or all of HBsAg, 
anti-HBc and anti-HBs) in the studied population was 60% (95% 
CI 54.8 - 64.9). The level of exposure to HBV in married persons 
was 75% (87/116). Although this value was higher than that for the 
unmarried of 56.4% (149/264), the difference was not statistically 
significant (p=0.14). Males (67.3% (70/104)) were insignificantly 
(p=0.2) more exposed than females (59.8% (165/276)). The 
prevalence of HBV based on HBsAg was 20% (95% CI 16.1 - 
24.4). The proportions of infection in the population between 
males and females were 19.2% (20/104) and 20.3% (56/276) 
respectively (p=0.82). Prevalence (based on HBsAg) in women of 
child-bearing age was 19.6% (53/270). The prevalences in married 
and unmarried patients were 23.3% (27/116) and 18.6% (49/264) 
respectively (p=0.74). In the 86 patients with available CD4+ cell 
count measurements, an insignificant difference (p=0.63) in HBV 
prevalence was seen in HIV patients with CD4+ cell counts ≤200 
cells/μl (27% (17/63)) compared with 21.7% (5/23) in patients with 
CD4+ cell counts >200 cells/μl (p=0.63).
The distribution of HBV infection among the age groups was (i) <20 
years old: 16.7% (2/12); (ii) 21 - 30 years old: 16.8% (17/101); (iii) 31 - 
40 years old: 19.0% (27/142); (iv) 41 - 50 years old: 26.7% (23/86); and 
(v) >50 years old: 18% (7/39). The prevalence of HBV differed across 
the various geographical areas of the province, ranging from 10.4% 
(11/106) in Mankweng to 28.5 % (55/193) in Bela Bela (p=0.000).
Occult hepatitis B infection in HIV/HBV co-infected 
patients
Occult HBV infection was assessed based on the presence of 
detectable HBV-DNA in reactive anti-HBc samples with negative 
HBsAg serology. Out of 380 patients, 304 were non-reactive to 
HBsAg; of the 304, 181 were serologically reactive for anti-HBc, 
and 61 of the 181 reactive anti-HBc samples had detectable HBV-
DNA identified by PCR targeting the core gene. Consequently, the 
prevalence of occult HBV infection in the study population was 
33.7% (95% CI 26.9 - 41.1).
Level of protection against HBV in HIV-infected patients
The level of protection against HBV was defined by a plasma anti-
HBs concentration of ≥10 mIU/ml. An overall protection rate of 
30% (95% CI 25.2 - 35.2) was observed. Protection did not differ 
significantly (p=0.2) between the genders − 28% (95% CI 22.4 - 34.0) 
in females and 35.1% in males (95% CI 31.9 -5 4.7). The level of 
protection in married patients of 35.6% (95% CI 26.4 - 45.6) was 
insignificantly higher (p=0.14) than that in unmarried patients 
27.6% (95% CI 22.0 - 33.7). Protection in patients with CD4 counts 
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≤200 cells/μl (19.7%, 95% CI 10.69 - 31.8) was also not significantly 
different (p=0.6) from patients with CD4 counts >200 cells/μl (15%, 
95% CI 3.2 - 37.9) (p=0.6).
The effects of DT4/3TC/EFV treatment on HBV 
infection in co-infected patients
HBV viral load outcome
Most of the patients entered therapy with low HBV viral loads, which 
were sustained during the first year of therapy. Twenty-one HIV/
HBV co-infected patients on HAART were involved in this aspect 
of the study. Nine of the 21 patients (42.9%) had undetectable viral 
loads before entering therapy, and 12/21 (57.1%) had detectable 
viral loads ranging from <6 IU/ml to 110 million IU/ml. Of the 9 
subjects with undetectable viral load, 7 maintained undetectable 
levels after 44 weeks on HAART and 2 reverted to detectable viral 
load within 44 weeks of treatment. At the end of 44 weeks, the 12 
patients with detectable viral loads prior to therapy had the following 
profile:  7/12 (58.3%) had undetectable DNA levels, 2/12 (16.7%) had 
a marginal decrease in viral loads lower than their initial values prior 
to therapy, 1/12 (8.3%) had maintained low DNA levels <6 IU/ml as 
at the beginning of therapy, and 2/12 (16.7%) had increased DNA 
levels over their starting values. The virological response in terms of 
reduction in viral loads between pretreatment and during treatment 
was 75% (9/12), and virological response based on reduction as well 
as maintenance of viral loads relative to pretreatment values in those 
with detectable viral loads was 83.3% (10/12). The average reduction 
of viral loads in samples with detectable differences in DNA viral 
loads (patients responding to therapy) between pretreatment and 
treatment at 44 weeks was 3.6 log10.
There was a reduction in viral load by a factor of as much as 
7 log10 in one patient. Of the 21 patients on therapy, 17 (81%) 
showed adequate response to therapy after 44 weeks with reduced 
or sustained low viral loads, and 4 (19%) showed clinical evidence 
(increased viral loads) of therapeutic failure.
Serological response
Serological response to HAART was 85.7% (95% CI 63.6 - 96.9) in 
terms of the number of patients with positive anti-HBe at 44 weeks 
of therapy. One sample (4.8%) had neither HBeAg nor anti-HBe 
detected, and 2/21 (9.5%) had failed to seroconvert.
Biochemical response
Biochemical response involved reverting abnormally high level of 
aminotransferase to its normal range (3 - 35 IU/l). Biochemical drug 
response was analysed on 24-weeks drug-experienced patients owing 
to unavailability of 44-week aminotransferase results. Twenty-one 
HAART-experienced patients started therapy; at 24 weeks, 8 had 
dropped out for various reasons, and 13 patients were available for 
analysis. The average level of aminotransferase in drug-experienced 
HIV/HBV co-infected patients prior to onset of therapy was 38.5 
IU/l. This level dropped to 34.5 IU/l and 31.9 IU/l at 12 and 24 weeks 
respectively in response to HAART therapy. At the onset of treatment 
with D4T/3TC/EFV, 7 (33.3%) of the 21 HIV/HBV co-infected 
patients had abnormally high ALT levels (39 - 189 IU/l) and 14/21 
(66.7%) had normal aminotransferase levels (10 - 35 IU/l). Of the 8 
patients without aminotransferase values at 24 weeks, 1 had abnormal 
levels (59 IU/l) and 7 had normal levels at the onset of therapy. 
Therefore, the 13 patients analysed at 24 weeks comprised 6 with 
abnormal and 7 with normal aminotransferase levels prior to therapy 
initiation. Four (66.7%) of the 6 with abnormally elevated levels 
of aminotransferase had adequate biochemical response reverting 
to normal levels after 24 weeks of therapy, 1/6 (16.7%) showed 
significant reduction of aminotransferase to a level just above the 
normal range, and 1/6 (16.7%) showed an elevated level above the 
starting value. Hence, 5/6 (83.3%) of the patients had reductions 
of abnormal aminotransferase level during HAART therapy. Five 
(71.4%) of the 7 patients with normal aminotransferase levels prior 
to therapy initiation maintained normal levels, and 2 (28.6%) had 
abnormally elevated levels at 24 weeks on treatment.
Discussion and conclusion
The current study assessed the prevalence, exposure and protection to 
HBV infection, and the efficacy of a D4T/3TC/EFV treatment regimen 
on HBV infection in a cross-sectional population of HIV-infected 
patients in Limpopo Province. The study population comprised black, 
adult South Africans at various stages of HIV disease.
The prevalence of HBV in the studied population, as defined by 
HBsAg serology, was 20%, which is twice as high according to the 
WHO classification of more than 8% for a high-prevalence region. 
Although the prevalence of HIV/HBV co-infection was observed to 
differ significantly among various sites in Limpopo Province, Bela 
Bela was noted as having the highest (28.5%). The HBV prevalence 
of 20% in HIV-infected patients is much higher than previously 
reported figures from different study settings in Gauteng and Eastern 
Cape provinces.[8,11,13] However, high prevalence rates have also been 
documented; for example, Hoffmann et al. reported a prevalence of 
20% among male mine workers in several regions of South Africa.[9] 
In Gauteng Province, exposure to HBV, based on HBsAg and anti-
HBc, of 39% was documented in HIV-infected women.[10]
The current study also examined the effect of declining CD4+ cell 
count on the prevalence of HBV, as reactivation is expected to be 
proportional to the level of immune depreciation.[14] The prevalence 
of HBV in HIV-infected patients with CD4+ count ≤200 cells/µl was 
shown to be insignificantly higher in patients  with CD4+ count >200 
cells/µl. However, a recent South African study showed a higher HBV 
prevalence in AIDS patients with CD4+ cell count <100 cells/µl.[15]
The study also showed that as much as 60% of HIV patients were 
exposed to HBV. All the patients analysed for the study were born at 
a time when vaccination against HBV was not part of the childhood 
vaccination programme. Therefore the anti-HBs results are probably 
due primarily to infection rather than to vaccination which is not 
routinely provided to adults. The high prevalence of HIV/HBV 
co-infection could be due to both high transmission of HBV in the 
general population early in life and HBV reactivation associated with 
HIV infection.
Occult HBV infection in HIV patients was found to be 33.7%.
The implication is that negativity to HBsAg serology may not always 
indicate the absence of infection. Previous studies in South Africa 
have shown that HBV DNA is significantly higher in HIV-infected 
than in HIV-negative patients, suggesting that HIV infection may be 
a risk factor for occult HBV infections.[12,16] This finding highlights 
the level of undetected active HBV infections that have the potential 
to affect antiretroviral therapy (ART) as their presence increases 
hepatotoxicity of ART with consequent limitation of their use.[17,18] 
Anti-HBs are known to confer protection against HBV at plasma 
levels ≥10 IU/ml. In the current investigation, 30% of HIV-infected 
patients were protected against HBV disease. A low level (28%) of 
protection against HBV in women, especially those of child-bearing 
age, predisposes most of them and their unborn/newborn children 
during pregnancy, labour and the postnatal period to HBV infection. 
The level of protection against HBV in the absence of vaccination is a 
reflection of (or consistent with) the high level of exposure and active 
HBV infection existing in this group of individuals, as reflected by 
the prevalence data.
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At the time of the study, first-line ART in South Africa was a 
combination of stavudine, lamivudine, and efavirenz. Lamivudine 
is recommended for the treatment of HBV infection. The efficacy of 
HAART against HBV was measured by means of viral, serological 
and biochemical responses. Adequate drug response against HBV 
was observed for more than 80% of the 21 patients analysed 
within a year of therapy based on these parameters. This limited 
observation, in terms of the sample size, is in contrast to the 
outcomes of a randomised study that showed little benefit in the 
use of a lamivudine-containing HAART for HIV/HBV-infected 
patients. [19] Although hepatotoxicity of HAART is increased by the 
presence of HBV, studies have shown that patients with high HBV-
DNA baseline levels have a higher risk of hepatotoxicity than non-
HBV-infected HIV patients.[9] Most of the patients in the current 
study had undetectable and low viral loads prior to therapy initiation 
and within a year on HAART, which may explain why the average 
level of aminotransferase was not significantly higher in these 
patients, concurring with the observation of Boyles and Cohen[8] that 
aminotransferase may be an insensitive marker for HBV infection. It 
could be assumed that most of the patients on HAART in the studied 
population had a lower risk of developing hepatotoxicity within the 
first year of treatment.
The findings presented here are apparently the first set of data 
from Limpopo Province on HIV/HBV co-infection. Nevertheless, 
it is important to interpret the results with some caution for the 
following reasons: (i) the effect of a small sample on the statistical 
differences in the exposure, prevalence and protection in terms of 
gender, marital status and CD4+ cell counts of the study population; 
(ii) viral load and biochemical response data were available for a 
small number of patients, which precludes preliminary conclusions 
on virological and biochemical outcomes based on the treatment 
regimen; (iii) consecutive samples for the assessment of drug efficacy 
were not consistent within the follow-up period and, coupled with 
lack of resistance data, makes it difficult to obtain a broader picture 
of response to lamivudine-containing HAART regimens on HBV 
disease; and (iv) the study was limited to HIV patients without 
a matched control group, and comprised individuals who might 
not have benefited from the inclusion of hepatitis B vaccine in the 
expanded programme on immunisation during their childhood, 
which might have contributed to higher prevalence values.
In conclusion: High levels of exposure and active HBV infection, and 
a moderate level of protection, were observed. Future studies employing 
a large sample size should look at mother-to-child transmission of 
HBV, and the impact of lamivudine-containing HAART on clinical 
outcomes and resistance development to lamivudine.
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